

Printed as of 12/16/2025

Disclosures

Personal Commercial (27)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Abbott Laboratories	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Alnylam	Research/Research Grants	Significant (>= \$5,000)	Other
Alnylam	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
AstraZeneca Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Avidity Biopharma	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Axon Therapeutics	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Baim Clinical Research Institute	Other - Adjudicator for CEC	Significant (>= \$5,000)	General Cardiology
Bayer Healthcare Pharmaceuticals	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
biofourmis	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Cytokinetics	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
endotronix	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
GlaxoSmithKline	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Medpace	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
New Amsterdam	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Novartis Corporation	Research/Research Grants	Research Grants Significant (>= \$5,000)	
Novartis Corporation	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Parexel	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Pfizer Inc	Research/Research Grants ‡ GARDEN TIMI-75	None (\$0)	Heart Failure and Cardiomyopathies
Regeneron	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
River2Renal	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Roche	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
scPharma	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Teva	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
TIMI Study Group	Other - Adjudication for CEC	Significant (>= \$5,000)	General Cardiology
Volta medical	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (2)

Year	Case Title	Represented	Description	Compensation
Self				
2019	Cardiomyopathy	Defendant	Fallure to diagnose and treat hemochromatosis involving the heart	Modest (< \$5,000)
2018	Out of Hospital Cardiac Arrest	Plaintiff	Failure to defibrillate patient with available AED during out of hospital arrest	Modest (< \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 8/26/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/Certified Education Attest at ion Agreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 8/26/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 8/26/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 8/26/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.